Publications

Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson NA, Li X, Li X, Metang LA, Mukherji A, Xu Q, Tirado CR, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y, Zhu H, Hanker AB, Raj GV, Zhu G, He HH, Wang Z, Arteaga CL, Liang H, Feng FY, Wang Y, Wang T, Mu P. ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer Discovery. (2024). Epub 20240408. doi: 10.1158/2159-8290.CD-23-0539. PubMed PMID: 38591846.
Rodriguez Tirado C, Wang C, Li X, Deng S, Gonzalez J, Johnson NA, Xu Y, Metang LA, Sundar Rajan M, Yang Y, Yin Y, Hofstad M, Raj GV, Zhang S, Lemoff A, He W, Fan J, Wang Y, Wang T, Mu P. UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. Oncogene. (2024). doi: 10.1038/s41388-023-02890-5.
Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson NA, Zhang Z, Tirado CR, Xu Y, Metang LA, Gonzalez J, Mukherji A, Ye J, Yang Y, Peng W, Tang Y, Hofstad M, Xie Z, Yoon H, Chen L, Liu X, Chen S, Zhu H, Strand D, Liang H, Raj G, He HH, Mendell JT, Li B, Wang T, Mu P. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. Cancer Cell. (2023). Epub 20230717. doi: 10.1016/j.ccell.2023.06.010. PubMed PMID: 37478850.
Deng S*, Wang C*, Wang Y*, Xu Y, Li X, Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J, Metang LA, Ye J, Tirado CR, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend DJ, Strand D, Hsieh JT, Li B, Raj G, Wang T, Mu P. Ectopic JAK/STAT Activation Enables the Transition to a Stem-like and Multi-lineage State Conferring AR-targeted Therapy Resistance. Nature Cancer (2022)
Lo UG, Chen YA, Cen JJ, Deng S, Luo JH, Zhau HY, Ho L,Lai CH, Mu P, Chung LWK, Hsieh JT. The driver role of JAK-STAT signaling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer. Clinical and Translational Medicine (2022)
de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell L, Vellky J, Brown R, Conger K, Paner G, Wang H, Platz E, De Marzo A, Mu P, Coloff J, Szmulewitz R, Vander Griend DJ. SOX2 Mediates Metabolic Reprogramming of Prostate Cancer Cells. Oncogene (2022)
Blatt EB, Kopplin N, Kumar S, Mu P, Conzen SD, Raj GV. Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview. Endocrine-Related Cancer (2021)
Zhang Z*, Zhou C*, Li X*, Barnes SD, Deng S, Hoover E, Chen C-C, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang C-H, Linton E, Chen X, Liang Y, Mason CE, Stanchina E de, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell (2020)
Zhang Z, Karthaus W, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes S, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, Stanchina E de, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell (2020)
Lin CJ, Yun EJ, Lo UG, Tai YL, Deng S, Hernandez E, Dang A, Chen YA, Saha D, Mu P, Lin H, Li TK, Shen TL, and Lai CH. The paracrine induction of prostate cancer progression by caveolin-1. Cell Death & Disease (2019)
Mu P, Zhang ZD, Bebelli M, Karthaus W, Hoover E, Wongvipat J, Ku SY, Chen CC, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Huang CH, de Stanchina E, Lowe SW , Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer. Science (2017)
Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (2017)
Han YC*, Vidigal JA*, Mu P*, Yao E, Singh I, lez AJGA, Concepcion CP, Bonetti C, Ogrodowski P, Carver B, Selleri L, Betel D, Leslie C, Ventura A. An allelic series of miR-17~92–mutant mice uncovers functional specialization and cooperation among members of a microRNA polycistron. Nature Genetics (2015)
Jin X, Mu P. Targeting breast cancer metastasis. Breast Cancer Basic and Clinical Research (2015)
Mu P, Deng S, Fan X. MicroRNAs in Prostate Cancer: Small RNAs with Big Roles. J Clin Cell Immunol (2015)
Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A. Intact p53-Dependent Responses in miR-34–Deficient Mice. Grimes HL, editor. PLoS Genetics (2012)
Yang JS, Phillips MD, Betel D, Mu P, Ventura A, Siepel AC, Chen KC, Lai EC. Widespread regulatory activity of vertebrate microRNA* species. RNA (2011)
Mu P*, Han YC*, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A. Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes & Development (2009) ed. 2009 Dec 15;23(24):2806–11.